




Contents lists available at ScienceDirect

International Journal of Cardiology

journal homepage: www.elsevier.com/locate/ijcard

Cardiac inflammation and microvascular procoagulant changes are decreased in second wave compared to first wave deceased COVID-19 patients

Linghe Wu^{a,1}, Umit Baylan^{b,1}, Britt van der Leeden^{c,1}, Bernadette Schurink^{d,1}, Eva Roos^{d,1}, Casper G. Schalkwijk^{e,1}, Marianna Bugiani^{f,1}, Paul van der Valk^{d,1}, Albert C. van Rossum^{g,1}, Sacha S. Zeerleder^{h,1,1}, Leo M.A. Heunks^{i,1}, Reinier A. Boon^{j,m,1}, Onno J. de Boer^{b,1}, Allard C. van der Wal^{b,1}, Hans W.M. Niessen^{k,1}, Paul A.J. Krijnen^{b,*,1}

^a Dept. of Pathology and Amsterdam Cardiovascular Sciences (ACS), Amsterdam University Medical Centre (AUMC), location VUmc, De Boelelaan 1017, 1081HV Amsterdam, the Netherlands

^b Dept. of Pathology and ACS, AUMC, location VUmc, the Netherlands

^c Dept. of Pathology and Amsterdam institute for Infection and Immunity, AUMC, the Netherlands

^d Dept. of Pathology, AUMC, location VUmc, the Netherlands

^e Dept. of Internal Medicine and Cardiovascular Research Maastricht, Maastricht University Medical Centre, P. Debyealaan 25, 6229 HX, Maastricht, the Netherlands

^f Dept. of Pathology, AUMC, location VUmc and AMC, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands

^g Dept. of Cardiology and ACS, AUMC, location VUmc, the Netherlands

^h Dept. of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Freiburgstrasse 18, 3010 Bern, Switzerland

ⁱ Dept. Intensive Care Medicine, AUMC, location VUmc, the Netherlands

^j Department of Physiology, AUMC, location VUmc, Amsterdam, the Netherlands

^k Dept. of Pathology and ACS and Dept. of Cardiac Surgery, AUMC, location VUmc, the Netherlands

^l Dept. for BioMedical Research, University of Bern, Murtenstrasse 35, 3008 Bern, Switzerland

^m Institute for Cardiovascular Regeneration, Centre for Molecular Medicine and German center for Cardiovascular Research (DZHK), Goethe University, Frankfurt am Main, Germany

ARTICLE INFO

Keywords:

COVID-19

First and second wave

Heart

Inflammation

Thrombosis microvasculature

ABSTRACT

Background: Compelling evidence has shown cardiac involvement in COVID-19 patients. However, the overall majority of these studies use data obtained during the first wave of the pandemic, while recently differences have been reported in disease course and mortality between first- and second wave COVID-19 patients. The aim of this study was to analyze and compare cardiac pathology between first- and second wave COVID-19 patients.

Methods: Autopsied hearts from first- ($n = 15$) and second wave ($n = 10$) COVID-19 patients and from 18 non-COVID-19 control patients were (immuno)histochemically analyzed. CD45+ leukocyte, CD68+ macrophage and CD3+ T lymphocyte infiltration, cardiomyocyte necrosis and microvascular thrombosis were quantified. In addition, the procoagulant factors Tissue Factor (TF), Factor VII (FVII), Factor XII (FXII), the anticoagulant protein Dipeptidyl Peptidase 4 (DPP4) and the advanced glycation end-product N^(ε)-Carboxymethyllysine (CML), as markers of microvascular thrombogenicity and dysfunction, were quantified.

Results: Cardiac inflammation was significantly decreased in second wave compared to first wave COVID-19 patients, predominantly related to a decrease in infiltrated lymphocytes and the occurrence of lymphocytic myocarditis. This was accompanied by significant decreases in cardiomyocyte injury and microvascular thrombosis. Moreover, microvascular deposits of FVII and CML were significantly lower in second wave compared to first wave COVID-19 patients.

Conclusions: These results show that in our cohort of fatal COVID-19 cases cardiac inflammation, cardiomyocyte injury and microvascular thrombogenicity were markedly decreased in second wave compared to first wave

* Corresponding author at: Department of Pathology, Amsterdam University Medical Centre, Room number L2-111, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.

E-mail address: paj.krijnen@amsterdamumc.nl (P.A.J. Krijnen).

¹ These authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.

<https://doi.org/10.1016/j.ijcard.2021.11.079>

Received 5 August 2021; Received in revised form 10 November 2021; Accepted 29 November 2021

Available online 3 December 2021

0167-5273/© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

patients. This may reflect advances in COVID-19 treatment related to an increased use of steroids in the second COVID-19 wave.

1. Introduction

Compelling evidence has been reported of cardiac involvement in coronavirus disease 2019 (COVID-19) patients. Elevated blood levels of cardiac Troponins and Creatine Kinase MB, indicative for acute myocardial injury, were found in 5% to 38% of hospitalized COVID-19 patients [2] and appear to associate with a fatal outcome [5]. In addition, cardiac magnetic resonance imaging studies have revealed myocardial abnormalities, including scar formation and myocardial edema, in patients with ongoing [6,7] and who recently recovered from COVID-19 [8]. Histopathological studies have shown increased cardiac inflammation consisting of infiltrating lymphocytes, macrophages and neutrophils, either or not coinciding with focal cardiomyocyte injury, in autopsied hearts of deceased COVID-19 patients [3,4,9,10] and in endomyocardial biopsies (EMB) of living COVID-19 patients [11,12], although some controversy exists about the incidence of myocarditis in COVID-19 patients [13–15]. In addition, evidence points to COVID-19-associated microvascular dysfunction and increased thrombogenicity in the heart. For instance, microvascular thrombosis has been observed in autopsied hearts of COVID-19 patients [3,10,16,17], which may predispose towards focal myocardial ischemia and myocardial injury.

During 2020 in many countries around the world, including Western Europe, the pandemic has surged in two distinct waves: the first between February/March and the end of May/June, and the second from September until the end of the year. The overall majority of studies on cardiac involvement in COVID-19 use data obtained during the first wave of the pandemic. Recently however, differences in patient demographics, disease course and mortality were reported between first and second wave COVID-19 [18–23]. These include a decrease in the proportion of hospitalized patients requiring ICU treatment or mechanical ventilation [18,19], an increase in younger patients that require hospitalization [19] and a decrease in case fatality rates [18,20] during the second wave. Whether and how COVID-19-related cardiac pathology compares between patients from the first and second wave of the pandemic is unknown.

We therefore analyzed and compared cellular inflammation, cardiomyocyte injury, microvascular thrombosis and markers of increased microvascular thrombogenicity and dysfunction in the hearts of COVID-19 patients who died during the first and second wave.

2. Methods

2.1. Patients

Heart tissue was obtained from 43 deceased patients: patients who died of clinical PCR-confirmed COVID-19 ($n = 25$) and control patients who died without any form of heart disease nor had inflammation of the heart ($n = 18$). Fifteen of the included COVID-19 patients died during the first wave of the pandemic (March or April 2020), while ten COVID-19 patients died during the second wave (between October and the end of December 2020). The controls all died >1 year before the COVID-19 outbreak. The general histopathological and immunological findings of the included first wave COVID-19 patients were previously published [3]. All autopsies were performed within 24 h after death. From each patient transmural sections of the posterior, lateral and anterior walls of the left ventricle (LV) and the septum were examined. These samples were formalin-fixed and paraffin embedded for (immuno)histochemical analyses. The diagnosis of LM was made in case the inflammatory infiltrate in the heart consisted of clusters of predominantly adherent T lymphocytes and to a lesser degree macrophages in the myocardium, that in all cases reached ≥ 14 leucocytes/mm² including up to 4

macrophages/mm² with the presence of CD3+ T-lymphocytes ≥ 7 cells/mm², accompanied by cardiomyocyte necrosis of non-ischemic origin, conform the European Society of Cardiology (ESC) criteria [24]. From eight first wave-, six second wave COVID-19 patients and five control patients, additional LV samples were taken and snap frozen in liquid N₂.

This study followed the guidelines of the ethics committee of the Amsterdam UMC (Amsterdam, the Netherlands), and conforms to the Declaration of Helsinki. The use of autopsy material for research after completion of the diagnostic process was consented in all cases.

2.2. Immunohistochemistry

Deparaffinized slide-mounted tissue-sections (4 μ m) were used. Endogenous peroxidases were blocked with 0.3% H₂O₂ in methanol for 30 min. Antigen retrieval was performed either by heat inactivation in Citrate buffer (pH = 6.0; CD68, CD3, C3d, FVII), Tris-EDTA buffer (pH = 9.0; CD31, TF) or enzymatically in 0.1% pepsin (37 °C for 30 min; FXII, CML). No antigen retrieval was performed for CD45 stainings. DPP4 (CD26) was analyzed on acetone-fixed frozen heart sections (5 μ m). Primary antibodies were added for 1 h at room temperature (RT): mouse-anti-human CD45 (1:100, Dako Santa Clara, USA; M0701), rabbit-anti-human CD68 (1:400, Dako; M0814), rabbit-anti-human CD3 (1:100, Dako; A0452), rabbit-anti-human C3d (1:1000, Dako; A0063), mouse-anti-human CD31 (1:50, Dako; M0823), mouse-anti-human TF (1:250, Biorbyt Cambridge, UK; ORB100189), mouse-anti-human FVII (1:100, Sanquin Research, Amsterdam, The Netherlands), mouse-anti-human FXII (1:25, Sanquin), mouse-anti-human CML (1:500 [25]) or mouse-anti-human CD26 (1:100, Bio-Rad, Lunteren, The Netherlands, MCA1317T). After a wash in PBS, the slides were incubated with goat-anti-rabbit/mouse Envision secondary antibodies (undiluted, Dako; K5007) for 30 min at RT. The stainings were visualized using 3,3'-diaminobenzidine (DAB)(0.1 mg/mL) and counterstained with hematoxylin. For each staining, slides incubated without a primary antibody were included as a negative control and these slides were found to be negative (data not shown).

2.3. Immunopathological and immunohistochemical analyses

All slides were analyzed using light microscopy and during immunoscoreing the researchers were blinded to the group allocation. Increases in extravasated CD45+ leukocytes, CD3+ T lymphocytes and CD68+ macrophages in the myocardium were semi-quantitatively determined to be either 'no' (no increase), 'focal' (small increases in certain areas), 'mild', 'moderate' or 'strong' (respectively mild, moderate or strong diffuse increases throughout the myocardium). In addition, the number of extravascular CD3+ cells in combination with up to 4 macrophages per mm² was determined in the LV endocardium in accordance with the ESC criteria [24,26]. Cardiomyocyte death was identified on C3d-stained slides. Microvascular fibrin platelet thrombi were identified CD31-stained slides. The number of intramyocardial blood vessels wherein endothelial cells stained positive for TF, FVII, FXII or DPP4 was counted. CML was quantified using intensity scoring as described previously [25]. For all markers the numbers of positive blood vessels were divided by the surface areas (in cm²) of the analyzed tissues. Immunoscoreing was performed by 3 independent researchers (L.W., B.U. and P. A.J.K.) and the inter-observation variation was below 10%.

2.4. Statistical analysis

All statistical analyses were performed with SPSS (version 22.0, Armonk, NY, USA). All graphs were designed using GraphPad Prism

software version 8.2.1 (San Diego, CA, USA). Differences between two groups were evaluated by independent Student *t*-test or Mann-Whitney *U* test for normal or non-normal distributed data respectively. Comparisons between multiple groups (more than two) were evaluated by either a one-way ANOVA or Kruskal-Wallis test with post-hoc Dunn's multiple comparisons for respectively normal or non-normal distributed data. Differences in semi-quantitatively determined myocardial inflammation as well as frequency distributions of non-parametric variables between patient groups were analyzed with Pearson Chi-square tests. Spearman rank correlation coefficients were used for correlation between groups with a non-normal distribution. *P*-values < 0.05 were considered statistically significant.

3. Results

3.1. Patient characteristics

The characteristics of the control ($n = 18$), first wave COVID-19 (Wave 1; $n = 15$) and second wave COVID-19 (Wave 2; $n = 10$) patients are presented in Supplementary Table 1. There was no significant difference in gender distribution between the three groups, with a majority of males in all groups (control $n = 14$ (78%); wave 1 COVID-19 $n = 12$ (80%); wave 2 COVID-19 $n = 6$ (60%)). The average age of the wave 1 and wave 2 COVID-19 patients (mean 68 and 67 years respectively) was significantly higher than the controls (mean 53 years; $p = 0.0053$ (wave 1) and $p = 0.0141$ (wave 2)). All COVID-19 patients were hospitalized. Prior to admittance, significantly more wave 1 ($n = 8$; 53%) than wave 2 COVID-19 patients ($n = 1$; 10%) were hypertensive (p




Fig. 1. Examples of inflammation, myocytolysis and microvascular thrombosis in the hearts of COVID-19 patients. Shown are examples of increased diffuse presence of CD68+ macrophages (A) and CD45+ leukocytes (B) in a wave 1 COVID-19 patient with diffuse cardiac inflammation (DCI), as well as immunohistochemical examples of clusters of adherent CD45+ leukocytes (C; arrow) and CD3+ T lymphocytes (D; arrows) in a wave 1 COVID-19 patient with lymphocytic myocarditis (LM). In addition an example of myocytolysis, detected as complement factor C3d + cardiomyocytes (E; arrow), and an example of intravascular aggregated CD31+ platelets and fibrin, indicative of a microvascular thrombus (F; arrow) in wave 1 COVID-19 patients.

= 0.027), whereas the other comorbidities, or cardiac symptoms did not differ between the groups. Thrombotic events, including deep-venous thrombosis and pulmonary embolism, were observed in 5 (33%) and 4 (27%) wave 1 and in 1 (10%) and 7 (70%) wave 2 patients respectively, indicative of increased systemic thrombogenicity. Of note, diffuse alveolar damage (DAD) was found to be equally severe in wave 1 and wave 2 patients.

3.2. Less cardiac inflammation in wave 2 than in wave 1 COVID-19 patients

All COVID-19 patients showed signs of increased cardiac inflammation, as confirmed immunohistochemically by increases in extravasated CD45+ leukocytes, CD3+ T lymphocytes and CD68+ macrophages in the myocardium (Fig. 1). In most patients this inflammatory infiltrate was diffusely present throughout the myocardium (Fig. 1A+B). Semi-quantitative analysis showed that wave 1 patients scored significantly higher amounts of CD45+ and of CD3+ cells in the myocardium than wave 2 patients ($p = 0.018$ and $p = 0.019$ respectively), while CD68+ macrophage scores were similar (Fig. 2A). In 7 out of 15 wave 1 patients the infiltrate consisted predominantly of clusters of adherent T lymphocytes and to a lesser degree macrophages in the myocardium, consistent with lymphocytic myocarditis (LM)(Fig. 1C+D) [24]. No LM was observed in wave 2 patients. The other 8 wave 1 patients and all wave 2 patients showed a more dispersed mixed infiltration of lymphocytes and macrophages that we refer to here as diffuse cardiac inflammation (DCI) [27]. In the LM patients of wave 1, the scores for CD45+ and CD3+ cells were significantly higher than in DCI

patients of wave 1 ($p = 0.006$ and $p = 0.03$ respectively) and of wave 2 ($p = 0.018$ and $p = 0.002$ respectively) (Fig. 2B). The scores between wave 1 and wave 2 DCI patients did not differ significantly, although the difference in scores for CD45+ cells was borderline significant ($p = 0.05$). Lastly, the number of extravascular CD3+ cells in combination with up to 4 macrophages per mm^2 in the ventricular endocardium of LM patients (29, SD = 4 cells/ mm^2) was significantly higher compared to wave 1 and wave 2 DCI patients ($p = 0.0087$ and $p = 0.0015$ respectively; Fig. 2C).

Injury in dispersed small cardiomyocyte clusters or individual cells, objectified by complement factor C3d immunostaining [3] (Fig. 1E) was observed in all wave 1 patients, but only in 4 out of 10 wave 2 patients ($p = 0.001$; Fig. 2D). Furthermore, intravascular thrombi, consisting of aggregated CD31+ platelets and fibrin were observed in the myocardium of 47% of wave 1 COVID-19 patients (Fig. 1F) [3], both in case of LM and DCI, while no intravascular thrombi were found in wave 2 patients ($p = 0.011$; Fig. 2D). No cardiac inflammation, nor intravascular thrombi were found in the control group.

3.3. Increased presence of coagulation factors in the cardiac microvasculature of COVID-19 patients

Procoagulant TF, FVII and FXII were all present on the endothelium of intramyocardial blood vessels of COVID-19 patients in both waves (Figs. 3A-C). The positive blood vessels were diffusely distributed throughout the myocardium. High levels of TF were also present in neutrophils (not shown). The numbers of TF+ blood vessels/ cm^2 in wave 1 and wave 2 patients were significantly higher than in controls (p




Fig. 2. Quantification of cardiac inflammation, myocytolysis and microvascular thrombosis in first and second wave COVID-19 patients. Stacked bars of (A): semi-quantitative analysis of the presence of extravasated CD45+ leukocytes, CD68+ macrophages and CD3+ T lymphocytes in the hearts of first wave (Wave 1) and second wave (Wave 2) COVID-19 patients and (B): subdivided between first wave COVID-19 patients with lymphocytic myocarditis (LM; $n = 7$) and diffuse cardiac inflammation (DCI; $n = 8$) and second wave patients with DCI ($n = 10$). Increases in inflammatory cells were quantified as either: no increase (dark green), focal (light green), mild (orange), moderate (dark red) or strong (black). For comparisons Pearson chi-square tests were used. (C): Graph: the number of extravasated CD3+ T lymphocytes supplemented with a maximum of 4 CD68+ macrophages per mm^2 in the ventricular endocardium of first wave LM and DCI and second wave DCI COVID-19 patients. Picture: example of extravasated CD3+ T lymphocytes in the ventricular endocardium (arrows). The bars represent mean \pm SD. For comparisons a Kruskal-Wallis test with Dunn's multiple comparison test was used. (D): The percentages in stacked bars of first- and second wave COVID-19 patients with (Yes; black) and without (No; white) cardiomyocyte injury (C3d+; left graph) and microvascular thrombi (right graph). For comparisons Pearson chi-square tests were used. n.s indicates not significant. * $p < 0.05$, ** $p < 0.01$ (exact p -values are given in the text). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)




Fig. 3. Examples of the presence of coagulation regulating factors in the cardiac microvasculature of COVID-19 patients. Immunohistochemical examples of the presence of the procoagulant factors Tissue Factor (A), Factor VII (B), Factor XII (C) in the endothelium of intramyocardial blood vessels of COVID-19 patients (arrows). Anticoagulant dipeptidyl peptidase 4 was detected via immunohistochemistry in the endothelium of most intramyocardial blood vessels of control patients (D; arrows), but was largely absent in the hearts of COVID-19 patients (E).

< 0.0001 and $p = 0.0005$ respectively; Fig. 4A), but were similar in both waves. In contrast, the number of FVII+ blood vessels/cm² in wave 1 patients were significantly higher than in controls ($p = 0.0001$), while in wave 2 patients these were similar to controls and significantly lower than in wave 1 patients ($p = 0.0362$; Fig. 4B). The number of FXII+ blood vessels/cm² again was significantly higher than controls in both waves ($p = 0.0017$ and $p = 0.0007$ respectively; Fig. 4C).

The anticoagulant serine peptidase DPP4 can cleave multimeric fibrin and thereby inhibit clot formation [28] and is expressed by cardiac endothelial cells [29]. In control hearts DPP4 was present in the endothelium of most intramyocardial blood vessels (Fig. 3D), whereas

both in wave 1 and wave 2 COVID-19 hearts we observed a significant decrease of DPP4+ blood vessels (Fig. 3E) compared with controls ($p = 0.0242$ and $p = 0.0044$ respectively; Fig. 4D).

3.4. CML is increased in the cardiac microvasculature of wave 1 but not of wave 2 COVID-19 patients

Cardiac microvascular dysfunction can coincide with increased levels of N(ε)-Carboxymethyllysine (CML; an advanced glycation end-product) [25,30].

CML was found in the endothelium and smooth muscle cells of




Fig. 4. Comparison of coagulation regulating factors and CML in the cardiac microvasculature between first and second wave COVID-19 and control patients. The number of blood vessels positive for the procoagulant factors Tissue Factor (A; TF), Factor VII (B; FVII), Factor XII (C; FXII) and anticoagulant dipeptidyl peptidase 4 (D; DPP4) are shown per cm² of left ventricular heart tissue in control patients (Con; *n* = 18) and first wave (Wave 1; *n* = 15) and second wave (Wave 2; *n* = 10) COVID-19 patients. (E): An immunohistochemical example of the presence N(ε)-Carboxymethyllysine (CML) in the endothelium of intramyocardial blood vessels of a COVID-19 patient (arrow) and the immunohistochemical (IH) score for CML per cm² in control patients (Con) and first- and second wave COVID-19 patients. (F): The number of blood vessels with weak, moderate and strong CML staining (staining intensities 1, 2, 3 respectively) in control (Con) and first- and second wave COVID-19 patients. Each point in the graphs represents the value of one individual patient, the bars represent mean ± SD. The bars represent mean ± SD. For comparisons Kruskal-Wallis tests with Dunn's multiple comparison tests were used. **p* < 0.05, ***p* < 0.01, ****p* < 0.001, *****p* < 0.0001 (exact *p*-values are given in the text).

intramyocardial blood vessels in COVID-19 patients, again diffusely distributed throughout the myocardium (Fig. 4E). The CML immunohistochemical (IH)-score/cm² in wave 1 patients was significantly higher than in controls (*p* = 0.0021), while in wave 2 patients these were similar to controls and significantly lower than in wave 1 patients (*p* < 0.0001; Fig. 4E). The increased CML IH-score in wave 1 COVID-19 hearts was mainly due to increased numbers of moderate and strong positive vessels (staining intensity 2 (*p* = 0.0003) and 3 (*p* = 0.0002) respectively), while in wave 2 patients the number of CML+ blood vessels of all staining intensities were significantly lower than wave 1 patients (*p* < 0.0001 for intensities 1 and 2, and *p* = 0.0003 for intensity 3) and in case of weak positive vessels even lower than in controls (*p* = 0.0017; Fig. 4F).

3.5. Coagulation and microvascular dysfunction factors are comparable between LM and DCI COVID-19 patients

The microvascular coagulation factor- and CML levels between wave 1 LM, wave 1 DCI and wave 2 DCI patients were then compared (Fig. 5A). The numbers of TF+ (Fig. 5A), FVII+ (Fig. 5B), FXII+ (Fig. 5C) blood vessels/cm² as well as the CML IH-score/cm² (Fig. 5D) and CML intensity scores (Fig. 5E) did not differ significantly between wave 1 LM and wave 1 DCI patients. In wave 2 DCI patients, the number of FVII+ blood vessels/cm² was significantly lower than wave 1 DCI patients (*p* = 0.0183; Fig. 5B). Also, the CML IH-scores/cm² in wave 2 DCI patients were significantly lower than in wave 1 DCI (*p* = 0.0072) and wave 1 LM patients (*p* = 0.0048). This was reflected in significantly lower CML intensity 1, 2 and 3 scores/cm² compared to wave 1 DCI (*p* = 0.0022, *p* = 0.0027, *p* = 0.0069 respectively) and wave 1 LM (*p* = 0.001, *p* =

0.0017, *p* = 0.0018 respectively) patients.

4. Discussion

The aim of this study was to compare COVID-19-related cardiac pathology between patients from the first and second wave of the SARS-CoV-2 pandemic. The extent of cardiac inflammation in second wave patients was significantly decreased compared to first wave patients, that appeared predominantly related to a decrease in infiltrated lymphocytes and occurrence of LM. This was accompanied by a decrease in cardiomyocyte injury and microvascular thrombosis in second wave patients, that coincided with a decreased presence of procoagulant factors in the cardiac microvasculature in second wave COVID-19 patients. These results highlight a markedly decreased cardiac pathology in deceased second wave COVID-19 patients.

The increase in cardiac inflammation and cardiomyocyte injury we observed in COVID-19 patients corresponds to previous studies that showed increases in extravasated lymphocytes and macrophages within the myocardium in deceased and in EMB of living COVID-19 patients [3,4,9–12]. However, we now show for the first time that the extent of cardiac inflammation and the occurrence of cardiomyocyte injury are significantly decreased in second wave patients. The moderate to high levels of diffuse macrophage infiltration in 93% of first wave cases correspond with the findings of Basso et al., who found increased macrophage infiltration in 86% of the studied COVID-19 patients [9]. However, in their study left ventricular cardiomyocyte injury was found only in the cases in which LM was diagnosed, whereas in our case series focal cardiomyocyte necrosis was present both in patients with LM and with DCI. Nonetheless, the decrease in especially lymphocytes in second




Fig. 5. Comparison of coagulation regulating factors and CML in the cardiac microvasculature between COVID-19 patients with lymphocytic myocarditis and with diffuse cardiac inflammation.

Shown are the number of blood vessels positive for Tissue Factor (A; TF), Factor VII (B; FVII), Factor XII (C; FXII), the CML IH-score (D) and intensity scores (E; number of blood vessels with weak, moderate and strong CML staining (staining intensities 1, 2, 3 respectively)) are shown per cm² in first wave (Wave 1) COVID-19 patients with LM (n=7) and with DCI (n=8) and second wave (Wave 2) COVID-19 patients with DCI (n=10). Each point in the graphs represents the value of one individual patient, the bars represent mean \pm SD. The bars represent mean \pm SD. For comparisons Kruskal-Wallis tests with Dunn's multiple comparison tests were used. * $p < 0.05$, ** $p < 0.01$ (exact p-values are given in the text).

wave patients corresponded with a decreased occurrence of cardiomyocyte injury. This suggests that cardiomyocyte injury is related more to infiltrated lymphocytes than macrophages, the levels of which remained high also in second wave patients.

In addition, we observed microvascular thrombosis in 47% of first wave cases, but in none of the second wave cases. As microvascular thrombosis can cause focal ischemia in the heart, it may contribute to the observed cardiomyocyte injury. The coinciding decreases in microvascular thrombosis and cardiomyocyte injury in second wave patients support this. Cardiac microvascular thrombosis in COVID-19 patients may be the result of the systemic hypercoagulability that often accompanies COVID-19 [31]. Indeed, deep vein thrombosis and pulmonary emboli were prevalent findings in our COVID-19 patients. However, the increased levels of TF, CML and decreased levels of DPP4, together with the increased deposits of the clotting factors FVII and FXII in the cardiac microvasculature of first wave COVID-19 patients, point to a procoagulant and pro-inflammatory phenotype of the microvascular endothelium that may locally facilitate the formation of thrombi. We previously showed a similar TF increase and DPP4 decrease in the cardiac microvascular endothelium of MI patients [29]. We also showed that inhibition of DPP4 enzymatic activity augmented TF expression and platelet adherence on HUVECs [29], emphasizing their importance in coagulation regulation on endothelial cells. The deposition of FVII and FXII indicates possible involvement of both extrinsic and intrinsic coagulation pathways. FVII can bind TF, whereas FXII is activated on negatively charged surfaces, including cell-free DNA. Both injured microvascular endothelium, that can release genomic material, and neutrophil extracellular traps (NETs), have been shown in the cardiac microvasculature of first wave COVID-19 patients [3], and may explain the presence of FXII. The decrease in microvascular thrombosis in second wave patients coincided with a decreased presence of FVII, arguing for an important role for the extrinsic pathway in COVID-19 related cardiac thrombosis.

CML is an indicator of microvascular inflammation and dysfunction

and we previously showed increased microvascular CML levels in the hearts of patients with diastolic heart failure, MI and myocarditis [25,30]. The significantly lower microvascular CML levels in second wave COVID-19 patients are in line with the decreased cardiac inflammation and microvascular thrombogenicity that we see in those patients.

The exact mechanisms underlying COVID-19 associated cardiac pathology so far remain to be elucidated. The observed LM suggests a viral etiology, which is supported by the detection of SARS-CoV-2 RNA in autopsied hearts and in EMB from living COVID-19 patients [11,32], although only in infiltrated macrophages, rather than in cardiomyocytes or endothelial cells [33]. The absence of LM in second wave patients would then imply a lower cardiac prevalence of SARS-CoV-2 during the second wave, although this remains to be established. Alternatively, high levels of circulating pro-inflammatory cytokines often accompany COVID-19 [34] and may also contribute to cardiac inflammation, injury and microvascular dysfunction as was shown previously in patients with long term sepsis [35]. Other factors may include increased cardiac stress due to impaired pulmonary perfusion [27], anxiety, and mechanical ventilation, that was shown to induce cardiac inflammation in rats [36].

Recent studies have reported a generally less severe disease course and decreased mortality in second wave COVID-19 compared to the first wave [18–23]. This may f.i. relate to shorter times between disease onset and admission and an increase in the proportion of younger patients that require hospitalization and advances in treatment. Younger patients tend to have less underlying cardiovascular co-morbidities and may therefore have a better outcome than older patients. However, in our case series, the ages of the first and second wave patients were similar and age is therefore an unlikely contributor to the decreased cardiac pathology. Unfortunately no data are available regarding the SARS-CoV-2 virus variants that infected our cohort. The prevalent variants in Europe and the Netherlands differed between the first and second wave. The most prevalent variants in the Netherlands in the first wave were

clades 19A, 20A and 20B [37]. In the summer of 2020 a new variant (clade 20E, also called EU1) spread through Europe [38], and this variant was prevalent in the Netherlands during the second wave [37]. Its transmissibility was found to be similar to previous variants [38] and no data has been reported that show differences between the pathogenesis induced by EU1 and earlier variants. In line herewith, the severity of DAD was similar in wave 1 and wave 2 patients. Notably, the alpha and delta variants only became prevalent in the Netherlands in 2021, after completion of patient inclusion. Therefore, although a difference in prevalent viral strains may have contributed to the observed differences in cardiac pathology, there is currently no data to support this.

Advances in treatment are perhaps the most likely explanation for the decreased cardiac pathology in second wave patients. Treatment of COVID-19 in the Netherlands has become more standardized during the second wave and generally conforms to treatment guidelines drawn up in collaboration with The Dutch Working Party on Antibiotic Policy (SWAB) [39]. These include f.i. the administration of the corticosteroid dexamethasone in patients with severe COVID-19. Dexamethasone was shown before to decrease cardiac inflammation in myocarditis patients [40] and to decrease cardiac microvascular CML levels in mice with doxorubicin-induced cardiotoxicity [41], suggesting that dexamethasone treatment may have contributed to the decreased cardiac pathology in the second wave. In addition, the increased use of high dose thromboprophylaxis may have contributed to the decreased microvascular thrombosis observed in second wave patients. Interestingly though, recent reports have shown survival benefit of high/moderate dose thromboprophylaxis in non-critically ill patients [42], but not in critically ill ICU patients [43] such as we have used for our study. Albeit, cardiac microvascular thrombosis was not measured in these studies.

It is noteworthy that whatever caused the decreased cardiac pathology in wave 2 patients did not affect the extent of damage to the lungs in our patients.

In conclusion, in this pathology study we show that cardiac inflammation, cardiomyocyte injury and microvascular thrombogenicity in our cohort of deceased COVID-19 patients were markedly decreased in second wave compared to first wave patients.

5. Study limitations

A limitation of this study is the relatively small number of patients in which these observations were made. In addition, this study has been performed in patients who died as a result of very severe COVID-19. Whether, and if so to what extent, the results we describe here also occur in patients with less severe COVID-19 remains to be studied.

Data sharing statement

The data that support the findings of this study (in deidentified form) are available from the corresponding author upon reasonable request.

Sources of funding

This work was supported by the China Scholarship Council (Beijing, China, grant number 201708260020 to LW); Heath Holland (The Hague, The Netherlands, Sector Life Sciences & Health (LSH) - Top-consortia for Knowledge and Innovation (TKI) grant, number LSHM19106 to BvdL).

Disclosures

No conflicts of interest exist.

Declaration of Competing Interest

None.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ijcard.2021.11.079>.

References

- [2] C. Bavishi, R.O. Bonow, V. Trivedi, J.D. Abbott, F.H. Messerli, D.L. Bhatt, Acute myocardial injury in patients hospitalized with COVID-19 infection: a review, *Prog. Cardiovasc. Dis.* (2020), <https://doi.org/10.1016/j.pcad.2020.05.013>.
- [3] B. Schurink, E. Roos, T. Radonic, E. Barbe, C.S.C. Bouman, H.H. de Boer, et al., Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study, *Lancet Microbe.* (2020), [https://doi.org/10.1016/S2666-5247\(20\)30144-0](https://doi.org/10.1016/S2666-5247(20)30144-0).
- [4] D. Wichmann, J.P. Sperhake, M. Lutgehetmann, S. Steurer, C. Edler, A. Heinemann, et al., Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study, *Ann. Intern. Med.* 173 (2020) 268–277, <https://doi.org/10.7326/M20-2003>.
- [5] S. Shi, M. Qin, B. Shen, Y. Cai, T. Liu, F. Yang, et al., Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China, *JAMA Cardiol.* 5 (2020) 802–810, <https://doi.org/10.1001/jamacardio.2020.0950>.
- [6] B.H. Chen, N.N. Shi, C.W. Wu, D.A. An, Y.X. Shi, L.D. Wesemann, et al., Early cardiac involvement in patients with acute COVID-19 infection identified by multiparametric cardiovascular magnetic resonance imaging, *Eur. Heart J. Cardiovasc. Imaging* (2021), <https://doi.org/10.1093/ehjci/jeab042>.
- [7] R.M. Inciardi, L. Lupi, G. Zacccone, L. Italia, M. Raffo, D. Tomasoni, et al., Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19), *JAMA Cardiol.* (2020), <https://doi.org/10.1001/jamacardio.2020.1096>.
- [8] V.O. Puntmann, M.L. Carerj, I. Wieters, M. Fahim, C. Arendt, J. Hoffmann, et al., Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19), *JAMA Cardiol.* (2020), <https://doi.org/10.1001/jamacardio.2020.3557>.
- [9] C. Basso, O. Leone, S. Rizzo, M. De Gaspari, A.C. van der Wal, M.C. Aubry, et al., Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study, *Eur. Heart J.* (2020), <https://doi.org/10.1093/eurheartj/ehaa664>.
- [10] M.C. Bois, N.A. Boire, A.J. Layman, M.C. Aubry, M.P. Alexander, A.C. Roden, et al., COVID-19-associated nonocclusive fibrin microthrombi in the heart, *Circulation* 143 (2021) 230–243, <https://doi.org/10.1161/CIRCULATIONAHA.120.050754>.
- [11] F. Escher, H. Pietsch, G. Aleshcheva, T. Bock, C. Baumeier, A. Elsaesser, et al., Detection of viral SARS-CoV-2 genomes and histopathological changes in endomyocardial biopsies, *ESC Heart Fail.* 7 (2020) 2440–2447, <https://doi.org/10.1002/ehf2.12805>.
- [12] S. Sala, G. Peretto, M. Gramegna, A. Palmisano, A. Villatore, D. Vignale, et al., Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection, *Eur. Heart J.* 41 (2020) 1861–1862, <https://doi.org/10.1093/eurheartj/ehaa286>.
- [13] S.E. Fox, L. Falgout, R.S. Vander Heide, COVID-19 myocarditis: quantitative analysis of the inflammatory infiltrate and a proposed mechanism, *Cardiovasc. Pathol.* 54 (2021), 107361, <https://doi.org/10.1016/j.carpath.2021.107361>.
- [14] M.K. Halushka, R.S. Vander Heide, Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations, *Cardiovasc. Pathol.* 50 (2021), 107300, <https://doi.org/10.1016/j.carpath.2020.107300>.
- [15] R. Kawakami, A. Sakamoto, K. Kawai, A. Gianatti, D. Pellegrini, A. Nasr, et al., Pathological evidence for SARS-CoV-2 as a cause of myocarditis: JACC review topic of the week, *J. Am. Coll. Cardiol.* 77 (2021) 314–325, <https://doi.org/10.1016/j.jacc.2020.11.031>.
- [16] D. Pellegrini, R. Kawakami, G. Guagliumi, A. Sakamoto, K. Kawai, A. Gianatti, et al., Microthrombi as a major cause of cardiac injury in COVID-19: a pathologic study, *Circulation* 143 (2021) 1031–1042, <https://doi.org/10.1161/CIRCULATIONAHA.120.051828>.
- [17] G. Guagliumi, A. Sonzogni, I. Pescetelli, D. Pellegrini, A.V. Finn, Microthrombi and ST-segment-elevation myocardial infarction in COVID-19, *Circulation* 142 (2020) 804–809, <https://doi.org/10.1161/CIRCULATIONAHA.120.049294>.
- [18] G. Fan, Z. Yang, Q. Lin, S. Zhao, L. Yang, D. He, Decreased case fatality rate of COVID-19 in the second wave: a study in 53 countries or regions, *Transbound. Emerg. Dis.* 68 (2021) 213–215, <https://doi.org/10.1111/tbed.13819>.
- [19] S. Iftimie, A.F. Lopez-Azcona, I. Vallverdu, S. Hernandez-Flix, G. de Febrer, S. Parra, et al., First and second waves of coronavirus disease-19: a comparative study in hospitalized patients in Reus, Spain, *PLoS One* 16 (2021), e0248029, <https://doi.org/10.1371/journal.pone.0248029>.
- [20] N. James, M. Menzies, P. Radchenko, COVID-19 second wave mortality in Europe and the United States, *Chaos* 31 (2021), 031105, <https://doi.org/10.1063/5.0041569>.
- [21] C. Karagiannidis, W. Windisch, D.F. McAuley, T. Welte, R. Busse, Major differences in ICU admissions during the first and second COVID-19 wave in Germany, *Lancet Respir. Med.* (2021), [https://doi.org/10.1016/S2213-2600\(21\)00101-6](https://doi.org/10.1016/S2213-2600(21)00101-6).
- [22] I. Mollinedo-Gajate, F. Villar-Alvarez, M.L.A. Zambrano-Chacon, L. Nunez-Garcia, L. de la Duena-Munoz, C. Lopez-Chang, et al., First and second waves of coronavirus disease 2019 in Madrid, Spain: clinical characteristics and hematological risk factors associated with critical/fatal illness, *Crit. Care Explor.* 3 (2021), e0346, <https://doi.org/10.1097/CCE.0000000000000346>.

- [23] S. Saito, Y. Asai, N. Matsunaga, K. Hayakawa, M. Terada, H. Ohtsu, et al., First and second COVID-19 waves in Japan: a comparison of disease severity and characteristics, *J. Inf. Secur.* 82 (2021) 84–123, <https://doi.org/10.1016/j.jinf.2020.10.033>.
- [24] A.L. Caforio, S. Pankuweit, E. Arbustini, C. Basso, J. Gimeno-Blanes, S.B. Felix, et al., Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, *Eur. Heart J.* 34 (2636–48) (2013), <https://doi.org/10.1093/eurheartj/ehf210>, 48a–48d.
- [25] A. Baidoshvili, P.A. Krijnen, K. Kupreishvili, C. Ciurana, W. Bleeker, R. Nijmeijer, et al., N(epsilon)-(carboxymethyl)lysine depositions in intramyocardial blood vessels in human and rat acute myocardial infarction: a predictor or reflection of infarction? *Arterioscler. Thromb. Vasc. Biol.* 26 (2006) 2497–2503, <https://doi.org/10.1161/01.ATV.0000245794.45804.ab>.
- [26] L. Woudstra, P.S. Biesbroek, R.W. Emmens, S. Heymans, L.J. Juffermans, A.C. van der Wal, et al., CD45 is a more sensitive marker than CD3 to diagnose lymphocytic myocarditis in the endomyocardium, *Hum. Pathol.* 62 (2017) 83–90, <https://doi.org/10.1016/j.humpath.2016.11.006>.
- [27] M.P. Begieneman, F.R. van de Goot, I.A. van der Bilt, A. Vonk Noordegraaf, M. D. Spreeuwenberg, W.J. Paulus, et al., Pulmonary embolism causes endomyocarditis in the human heart, *Heart* 94 (2008) 450–456, <https://doi.org/10.1136/hrt.2007.118638>.
- [28] R. Mentlein, E. Heymann, Dipeptidyl peptidase IV inhibits the polymerization of fibrin monomers, *Arch. Biochem. Biophys.* 217 (1982) 748–750, [https://doi.org/10.1016/0003-9861\(82\)90556-2](https://doi.org/10.1016/0003-9861(82)90556-2).
- [29] P.A. Krijnen, N.E. Hahn, I. Kholova, U. Baylan, J.A. Sipkens, F.P. van Alphen, et al., Loss of DPP4 activity is related to a prothrombotic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients, *Basic Res. Cardiol.* 107 (2012) 233, <https://doi.org/10.1007/s00395-011-0233-5>.
- [30] L. van Heerebeek, N. Hamdani, M.L. Handoko, I. Falcao-Pires, R.J. Musters, K. Kupreishvili, et al., Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension, *Circulation* 117 (2008) 43–51, <https://doi.org/10.1161/CIRCULATIONAHA.107.728550>.
- [31] N. Mackman, S. Antoniak, A.S. Wolberg, R. Kasthuri, N.S. Key, Coagulation abnormalities and thrombosis in patients infected with SARS-CoV-2 and other pandemic viruses, *Arterioscler. Thromb. Vasc. Biol.* 40 (2020) 2033–2044, <https://doi.org/10.1161/ATVBAHA.120.314514>.
- [32] D. Lindner, A. Fitzek, H. Brauninger, G. Aleshcheva, C. Edler, K. Meissner, et al., Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases, *JAMA Cardiol.* (2020), <https://doi.org/10.1001/jamacardio.2020.3551>.
- [33] G. Tavazzi, C. Pellegrini, M. Maurelli, M. Belliato, F. Sciutti, A. Bottazzi, et al., Myocardial localization of coronavirus in COVID-19 cardiogenic shock, *Eur. J. Heart Fail.* 22 (2020) 911–915, <https://doi.org/10.1002/ejhf.1828>.
- [34] R.J. Jose, A. Manuel, COVID-19 cytokine storm: the interplay between inflammation and coagulation, *Lancet Respir. Med.* (2020), [https://doi.org/10.1016/S2213-2600\(20\)30216-2](https://doi.org/10.1016/S2213-2600(20)30216-2).
- [35] M.A. Rossi, M.R. Celes, C.M. Prado, F.P. Saggioro, Myocardial structural changes in long-term human severe sepsis/septic shock may be responsible for cardiac dysfunction, *Shock* 27 (2007) 10–18, <https://doi.org/10.1097/01.shk.0000235141.05528.47>.
- [36] M.C. Kneyber, R.P. Gazendam, H.W. Niessen, J.W. Kuiper, C.C. Dos Santos, A. S. Slutsky, et al., Mechanical ventilation during experimental sepsis increases deposition of advanced glycation end products and myocardial inflammation, *Crit. Care* 13 (2009) R87, <https://doi.org/10.1186/cc7911>.
- [37] Nextstrain.org, SARS-CoV-2 Phylogeny. https://nextstrain.org/groups/ncov/netherlands?f_country=Netherlands&r=division, 2021.
- [38] E.B. Hodcroft, M. Zuber, S. Nadeau, T.G. Vaughan, K.H.D. Crawford, C.L. Althaus, et al., Spread of a SARS-CoV-2 variant through Europe in the summer of 2020, *Nature* 595 (2021) 707–712, <https://doi.org/10.1038/s41586-021-03677-y>.
- [39] (SWAB) TDWpAP, Medicamenteuze Behandeling Voor Patiënten Met COVID-19 (Infectie Met SARS-CoV-2). <https://swab.nl/nl/covid-19>, 2020.
- [40] U. Kuhl, H.P. Schultheiss, Treatment of chronic myocarditis with corticosteroids, *Eur. Heart J.* 16 (Suppl O) (1995) 168–172, https://doi.org/10.1093/eurheartj/16.suppl_o.168.
- [41] A.M. Bruynzeel, M.A. Abou El Hassan, C. Schalkwijk, J. Berkhof, A. Bast, H. W. Niessen, et al., Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice, *Br. J. Cancer* 96 (2007) 937–943, <https://doi.org/10.1038/sj.bjc.6603640>.
- [42] A. Investigators, Investigators AC-a, Investigators R-C, P.R. Lawler, E.C. Goligher, J.S. Berger, et al., Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19, *N. Engl. J. Med.* 385 (2021) 790–802, <https://doi.org/10.1056/NEJMoa2105911>.
- [43] R.-C. Investigators, Investigators AC-a, Investigators A, E.C. Goligher, C. A. Bradbury, B.J. McVerry, et al., Therapeutic anticoagulation with heparin in critically ill patients with Covid-19, *N. Engl. J. Med.* 385 (2021) 777–789, <https://doi.org/10.1056/NEJMoa2103417>.